Immunovant Inc. Reports Q1 2026 Results and Updates on Development Pipeline
Immunovant Inc. (Nasdaq: IMVT) released its financial results for the fiscal first quarter ended June 30 2026 on August 6, 2026, accompanied by a corporate update on its ongoing clinical programs.
Financial Performance
- Cash Position – As of June 30 2026, the company reported cash and cash equivalents of $797.8 million.
- Research & Development Expenses – R&D spending for the quarter reached $14 million.
- Operating Outlook – The available cash is projected to sustain the planned commercial launch of IMVT‑1402 in Graves’ disease (GD) based on the current operating plan.
Clinical‑Development Highlights
The company maintains that all six announced indications for IMVT‑1402 remain on schedule:
| Indication | Status | Expected Data Release |
|---|---|---|
| Graves’ disease (GD) | On track | Topline data in 2027 |
| Myasthenia gravis (MG) | On track | Topline data in 2027 |
| Chronic inflammatory demyelinating polyneuropathy (CIDP) | On track | Topline data in 2028 |
| Difficult‑to‑treat rheumatoid arthritis (D2T RA) | Registrational program | Further updates expected |
| Sjögren’s disease (SjD) | On track | Topline data in 2028 |
| Cutaneous lupus erythematosus (CLE) | Proof‑of‑concept | Topline data in second half of 2026 |
Additional developments reported by the company include:
- Proof‑of‑concept trial for IMVT‑1402 in CLE is underway, with topline data expected later in 2026.
- The company anticipates topline data for the D2T RA program in the second half of 2026 and for the GD and MG programs in 2027.
Upcoming Communications
Immunovant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss the quarter’s results and provide further business updates.
Market Context
As of August 4, 2026, Immunovant’s share price stood at $39.28, with a 52‑week range between $14.32 and $41.23. The company’s market capitalization is approximately $8.08 billion. The stock trades on the Nasdaq under the ticker IMVT.
